Intrinsic Imaging Awarded Phase II Clinical Trial for Glioblastoma Multiforme

Boston, MA / San Antonio, TX — April 9, 2015 — Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant medical imaging core lab specializing in providing services for clinical trials, announced today that it has been awarded a Phase II clinical trial to evaluate a novel treatment for patients with Glioblastoma Multiforme (GBM).

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and imaging charter development, site qualification, site training and management, image transfer, blinding and processing of images acquired by magnetic resonance imaging (MRI). Tumor assessments will be performed by Intrinsic Imaging's board-certified, fellowship-trained neuroradiologists.

Glioblastoma Multiforme is the most common and most aggressive primary malignant brain tumor in adults. Despite advances in surgery, radiation and chemotherapy, prognosis remains poor and there is a significant unmet need for novel therapies.